Challenges With ICD Leads Are Under Control, St. Jude Tells Investors
This article was originally published in The Gray Sheet
Executive Summary
The company was prepared for FDA’s recent warning letter, executives said on an earnings call. But the scrutiny is not over, analysts suggest.